Medpage Today on MSN12d
Treatment of Oligometastatic EGFR-Mutant Lung Cancer
EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC). However, ...
Cure Today14h
FDA Grants Breakthrough Therapy Designation to Sac-TMT for Some with NSCLC
The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...
Merck gets FDA Breakthrough Therapy designation for sac-TMT
Merck (NYSE:MRK) said the FDA has granted Breakthrough Therapy designation for its antibody drug conjugate sacituzumab ...
MRK: Sac-TMT Gets FDA Breakthrough Therapy Designation For EGFR-mutated Advanced Or Metastatic NSCLC
Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...
Cure Today12d
Radiotherapy and EGFR-TKIs May Improve Treatment Outcomes in Lung Cancer
CURE® spoke with a lung cancer treatment expert about study findings showing survival benefits with the addition of ...
Merck: FDA grants Breakthrough Therapy designation to sacituzumab tirumotecan
Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients with advanced or metastatic nonsquamous non-small cell ...
Cancer Therapy Advisor22h
Top Lung Cancer Research of 2024
This page includes links to articles highlighting the top lung cancer research published on Cancer Therapy Advisor in 2024.
mskcc.org8d
How MSK Cares for a Young Woman Living With Stage 4 EGFR Lung Cancer
Learn how a young woman diagnosed with stage 4 non-small cell lung cancer had many treatment options because she came to MSK first.
He's a doctor studying why lung cancer rates are rising in Asian Americans with no smoking history. Now he's also a patient.
Stanford University medical professor Dr. Bryant Lin was diagnosed with stage IV lung cancer despite never smoking. Now, he's ...
BioSpace1d
AstraZeneca/Daiichi Sankyo, BioNTech, Merus to Present Promising Cancer Therapies at ESMO Asia 2024
At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus ...
Alpha Biopharma Received NMPA Approval For Zorifertinib Tablets (Zorifer®), The World's First EGFR-TKI For Lung Cancer With Brain Metastases.
Zorifertinib is the first drug in the world to launch a registration clinical trial specifically for advanced NSCLC with CNS metastases and achieve remarkable results. It is also the only* EGFR ...